Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 9:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 656 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Thyroid Disease Clear all

Conditions: Thyroid Carcinoma
Interventions: LBH589; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 3
States / cities: Green Bay, Wisconsin • Madison, Wisconsin • Milwaukee, Wisconsin

Conditions: Metastatic Breast Cancer, Thyroid Dysfunction
Interventions: Triiodothyronine (T3); Drug
Lead sponsor: Aultman Health Foundation; Other
Eligibility: 18 Years to 105 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Canton, Ohio

Conditions: Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
Interventions: pazopanib hydrochloride, iodine I 131; Drug · Radiation
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Biliary Tract Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, GastroEsophageal Cancer, Head and Neck Cancer, Hepatocellular Cancer, Non-small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Renal Cancer, Thyroid Cancer, Urothelial Carcinoma (UC), Cholangiocarcinoma, Mesothelioma, Gallbladder Cancer, Ovarian Cancer
Interventions: MDX2001; Drug
Lead sponsor: ModeX Therapeutics, An OPKO Health Company; Industry
Eligibility: 18 Years and older
Enrollment: 330 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 6
States / cities: Denver, Colorado • Miami, Florida • Boston, Massachusetts + 3 more

Conditions: Hypothyroidism
Interventions: Growth hormone, Growth hormone treatment and puberty; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer
Interventions: filgrastim, pegfilgrastim, cisplatin, doxorubicin hydrochloride, fosbretabulin disodium, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 3
States / cities: Detroit, Michigan • Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: Papillary Thyroid Cancer
Interventions: Radiofrequency Ablation; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypothyroidism, Trisomy 21
Interventions: Liquid stable levothyroxine (L-T4) Tirosint-SOL, Oral tablet levothyroxine (L-T4); Drug
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 2 Months to 4 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Hypothyroidism, Thyroid Neoplasms
Interventions: Thyrogen; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Postsurgical Hypothyroidism, Hypothyroidism
Interventions: thyroidectomy, levothyroxine in thyroidectomy patients; Procedure · Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 75 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Hypothyroidism
Interventions: Isovue; Drug
Lead sponsor: Bracco Diagnostics, Inc; Industry
Eligibility: Up to 3 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 4
States / cities: Phoenix, Arizona • Omaha, Nebraska • Akron, Ohio + 1 more

Conditions: Primary Hypothyroidism.
Interventions: Levothyroxine, Desiccated thyroid extract; Drug
Lead sponsor: Walter Reed National Military Medical Center; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 2
States / cities: Bethesda, Maryland

Conditions: Differentiated Thyroid Cancer (DTC), Papillary Thyroid Microcarcinoma, Papillary Thyroid Carcinoma
Interventions: Decision Aid; Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypothyroidism
Interventions: Calcitonin; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 88 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Head and Neck Cancer
Interventions: gene expression analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, diagnostic laboratory biomarker analysis, immunohistochemistry staining method, needle biopsy; Genetic · Other · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Solid Tumor, Anaplastic Thyroid Cancer
Interventions: Crolibulin, Cisplatin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thyroid Eye Disease
Interventions: Efgartigimod PH20 SC, Placebo PH20 SC; Combination Product · Other
Lead sponsor: argenx; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 16
States / cities: Beverly Hills, California • Irvine, California • Los Angeles, California + 13 more

Conditions: Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer
Interventions: TT-00420, Nab-Paclitaxel; Drug · Combination Product
Lead sponsor: TransThera Sciences (Nanjing), Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Duarte, California • Chicago, Illinois • New Brunswick, New Jersey + 3 more

Conditions: Thyroid Cancer
Interventions: •Referral to Genetic Counselor, if indicated; Genetic
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: Not listed
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Dabrafenib, Dabrafenib Mesylate, Echocardiography Test, Lapatinib, Lapatinib Ditosylate, Magnetic Resonance Imaging, Multigated Acquisition Scan, Positron Emission Tomography; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Diagnoses Disease
Interventions: Determination of risk of malignancy of these thyroid lesions; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Bioavailability, Bioequivalence
Interventions: TEPEZZA, EDP; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Solid Tumors Harboring NTRK Fusion
Interventions: BAY2757556 (Larotrectinib, Vitrakvi); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 18
States / cities: Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more

Conditions: Papillary Thyroid Carcinoma
Interventions: GSK2118436; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Trial of LBH589 in Metastatic Thyroid Cancer

Study of Euthyroid Hypothyroxinemia in Metastatic Breast Carcinoma

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Radiofrequency Ablation of Papillary Thyroid Microcarcinoma

Use of Liquid Stable Levothyroxine in Trisomy 21 Pediatric Patients

Study of Radioiodine (131-I) Uptake Following Administration of Thyrogen and Hypothyroid States During Thyroid Hormone Withdrawal.

Is Levothyroxine Alone Adequate Thyroid Hormone Replacement?

Thyroid Function of Pediatric Subjects Following Isovue® Administration

Desiccated Thyroid Extract and Levothyroxine for Hypothyroidism Treatment

Decision Aid Efficacy in Low Risk Thyroid Cancer

Hypothyroidism Treated With Calcitonin

Genetic Analysis in Diagnosing Thyroid Cancer in Patients With Thyroid Nodules

A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)

A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease

Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors

Hereditary Risk Factors for Thyroid Cancer

Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery

Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)

A Study of TEPEZZA Subcutaneous Administration in Healthy Adults

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

Re-differentiation of Radioiodine-Refractory BRAF V600E-mutant Papillary Thyroid Carcinoma With GSK2118436